In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study

References

• Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92:835–841.
   PubMed Web of Science ®Google Scholar
• Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, . Left atrial volume: Important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001;76:467–475.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, . Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41: 218–223.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Heller EN, Mitchell LB, Chandler M, Slater W, Green M, . Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005;45:2026–2033.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE study. J Am Coll Cardiol. 2005;45: 712–719.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, . Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The LIFE study. J Am Coll Cardiol. 2005;45:705–711.
   PubMed Web of Science ®Google Scholar
• Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, . Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 2007;49:311–316.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, . Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: The LIFE study. Hypertension. 2000;35:6–12.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlöf B, Smith G, . Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Am J Cardiol. 2001;87:54–60.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Smith G, Gerdts E, Dahlöf B, Nieminen MS, Papademetriou V, . Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol. 2000;85: 466–472.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Bella JN, Boman K, Gerdts E, Nieminen MS, Rokkedal J, . Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press. 2001; 10:74–82.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, de Faire U, Fyhrquist F, . Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Hypertension. 1998;32:989–997.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000;36:766–773.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, . Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350–2356.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Hedner T, Ibsen H, . The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Am J Hypertens. 1997;10:705–713.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, . Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
   PubMed Web of Science ®Google Scholar
• Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, . Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999;34: 1625–1632.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61–65.
   PubMed Web of Science ®Google Scholar
• Ilercil A, O'Grady MJ, Roman MJ, Paranicas M, Lee ET, Welty TK, . Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: The Strong Heart Study. J Am Soc Echocardiogr. 2001;14:601–611.
   PubMed Web of Science ®Google Scholar
• Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M, . Prevalence and correlates of aortic regurgitation in American Indians: The Strong Heart Study. J Am Coll Cardiol. 2000;36:461–467.
   PubMed Web of Science ®Google Scholar
• Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, . Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). Am J Cardiol. 2001;87:298–304.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362.
   PubMed Web of Science ®Google Scholar
• Chen C, Wang HW, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med. 2003;22:3449–3459.
   PubMed Web of Science ®Google Scholar
• Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, . Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242–1248.
   PubMed Web of Science ®Google Scholar
• Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197–2204.
   PubMed Web of Science ®Google Scholar
• Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, . Renin–angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004;109:1640–1646.
   PubMed Web of Science ®Google Scholar